Previous studies suggest that cotargeting of PYK2 and EGFR could be beneficial for basal‐like patients with high EGFR levels,[16] and other studies suggest that immunosuppressive activity of TAMs is associated with upregulation of PD‐L1 and immune escape in TNBC.[15] Our finding that PYK2 inhibition reduced the number of TAMs and their pro‐tumorigenic phenotype suggests that PYK2 inhibition may sensitize BC to anti‐PDL1 blockade. Here, CD274 is linked to breast cancer.